Physician profile
Jeffrey Arthur Dann
NPI 1174574180
$112,023.57
in general payments reported to CMS, 2019-2025
38 companies · $43K in 2025
The $43K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $202 · 2021: $907 · 2022: $2,534 · 2023: $667 · 2024: $42K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $83K · Travel and Lodging: $1,975 · Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $83,253.62 |
| Travel and Lodging | $1,974.78 |
| Food and Beverage | $727.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $73,210.02 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter, Optilume Urethral Drug Coated Balloon |
| Uromedica, Incorporated | $15,413.52 | 2019 | |
| I/O Urology Corp. | $7,899.81 | 2025 | Carepath |
| Calyxo, INC. | $4,887.50 | 2022-2024 | Cvac Aspiration System |
| Srs Medical Systems, INC. | $4,462.50 | 2019 | |
| Bioprotect Medical, INC. | $1,487.50 | 2024 | Bioprotect Balloon Implant System |
| Procept Biorobotics Corporation | $1,228.75 | 2019-2025 | Aquabeam System |
| Astellas Pharma US INC | $756.31 | 2019-2023 | Xtandi |
| C. R. Bard, INC. & Subsidiaries | $455.00 | 2021 | |
| Pfizer INC. | $272.06 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $214.77 | 2019-2021 | |
| Janssen Biotech, INC. | $212.58 | 2019-2023 | Erleada |
| Sun Pharmaceutical Industries INC. | $184.34 | 2019-2022 | |
| Allergan, INC. | $147.34 | 2019-2021 | |
| Myovant Sciences INC. | $124.23 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $114.87 | 2021-2023 | |
| Tolmar Pharmaceuticals, INC. | $110.80 | 2019-2022 | |
| Amgen INC. | $102.54 | 2019 | |
| Merck Sharp & Dohme LLC | $87.57 | 2022-2023 | Lynparza, Keytruda |
| Boston Scientific Corporation | $78.96 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.94 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $49.11 | 2022 | |
| Medtronic, INC. | $47.21 | 2022-2024 | Interstim |
| Astrazeneca Pharmaceuticals Lp | $45.26 | 2021 | |
| Tolmar, INC. | $44.95 | 2023 | |
| Dendreon Pharmaceuticals LLC | $41.52 | 2020 | |
| Urogen Pharma, INC. | $41.12 | 2022-2023 | Jelmyto |
| Urovant Sciences INC | $40.67 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $39.93 | 2023-2025 | Prolaris |
| Sumitomo Pharma America, INC. | $37.66 | 2023 | Gemtesa |
| Accord Healthcare, INC. | $34.65 | 2023 | |
| Telix Pharmaceuticals | $23.93 | 2022 | |
| Coloplast Corp | $22.44 | 2019 | |
| Dentsply Ih INC. | $17.13 | 2019 | |
| Bard Access Systems, INC. | $12.08 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Dann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.